METROPOLIS - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.7
| Stock Code | METROPOLIS | Market Cap | 11,105 Cr. | Current Price | 536 ₹ | High / Low | 600 ₹ |
| Stock P/E | 68.2 | Book Value | 64.0 ₹ | Dividend Yield | 0.37 % | ROCE | 16.8 % |
| ROE | 13.1 % | Face Value | 2.00 ₹ | DMA 50 | 497 ₹ | DMA 200 | 482 ₹ |
| Chg in FII Hold | -1.25 % | Chg in DII Hold | 1.07 % | PAT Qtr | 43.3 Cr. | PAT Prev Qtr | 38.0 Cr. |
| RSI | 60.4 | MACD | 13.6 | Volume | 1,47,434 | Avg Vol 1Wk | 2,71,287 |
| Low price | 411 ₹ | High price | 600 ₹ | PEG Ratio | 12.5 | Debt to equity | 0.11 |
| 52w Index | 65.9 % | Qtr Profit Var | 82.6 % | EPS | 7.60 ₹ | Industry PE | 43.9 |
📊 Analysis:
Metropolis Healthcare (METROPOLIS) is trading at ₹536, above both its 50 DMA (₹497) and 200 DMA (₹482), showing short-term strength. RSI at 60.4 indicates bullish momentum, while MACD at 13.6 confirms positive bias. Current volume (1.47 lakh) is significantly below the weekly average (2.71 lakh), limiting intraday participation. Valuations are stretched (P/E 68.2 vs industry 43.9), with weak PEG ratio (12.5). Fundamentals show moderate efficiency (ROE 13.1%, ROCE 16.8%) and strong profit growth (+82.6% QoQ), making it a tactical intraday candidate.
💡 Optimal Buy Zone:
₹530–₹540 if price sustains above VWAP and DMA support.
🎯 Exit Levels:
- Profit-taking: ₹555–₹565 (near short-term resistance).
- Stop-loss: ₹520–₹525 (below intraday support).
⏱️ Intraday Exit Strategy:
If already holding, consider exiting when
- RSI dips below 58 intraday.
- Price fails to hold above ₹530 support.
- Volume remains weak (<1.5 lakh) with stagnating price action.
---
### ✅ Positive
- PAT growth (₹38 Cr. → ₹43.3 Cr.) +82.6%.
- EPS at ₹7.60 reflects earnings improvement.
- Trading above both DMA 50 and DMA 200.
- DII holdings increased (+1.07%).
- Debt-to-equity ratio at 0.11, low leverage.
### ⚠️ Limitation
- High valuation (P/E 68.2 vs industry 43.9).
- PEG ratio at 12.5, poor valuation-to-growth alignment.
- Dividend yield modest at 0.37%.
- Volume below weekly average, limiting intraday strength.
### 📉 Company Negative News
- FII holdings decreased (-1.25%).
- Valuation premium raises caution for momentum trades.
### 📈 Company Positive News
- Strong quarterly profit growth (+82.6%).
- Technical breakout above DMA levels.
- DII accumulation supports investor confidence.
### 🏭 Industry
- Diagnostics sector average P/E at 43.9, Metropolis trades at a premium (68.2).
- Sector outlook supported by rising healthcare demand and diagnostic expansion.
### 📌 Conclusion
Metropolis Healthcare is a speculative intraday candidate with valuation risks but strong profit growth and technical support. Best suited for tactical trades near ₹530–₹540 with exits around ₹555–₹565. Maintain strict stop-loss discipline below ₹525 to protect against intraday reversals.
This frames METROPOLIS as a speculative intraday trade with valuation risks but strong profit momentum. Would you like me to extend this into a swing trade setup with medium-term entry/exit zones and sector overlays?